Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings Inc.

Oppenheimer analyst reiterated a Buy rating on Xeris Pharmaceuticals today and set a price target of $18.00. Currently, the analyst consensus on Xe...

Oppenheimer Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Xeris Pharmaceuticals today and set a price target of $10.00. Folkes covers the H...

H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xeris Pharmaceuticals (XERS) and Tarsus Pharmaceutic...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$6.32	+1.44%	1.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XERS	$6.32	+1.4%	1.66M
3
4
5
6

XERS

XERS

Get Xeris Biopharma Holdings Inc. Data in Excel

Get Xeris Biopharma Holdings Inc. Data in Excel